Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Completes $22M Series F Round

NEW YORK (GenomeWeb) – Biodesix said today that it has completed a $22 million Series F financing round.

The company raised most of the funds through the sale of preferred stock and other securities — the total amount also includes capital previously raised through convertible debt that was converted into equity in this round.

Biodesix said it plans to use the funds for general corporate purposes and for ongoing development of new products, including diagnostic tests for use with immunotherapies and companion diagnostics for the cancer drug ficlatuzumab. The company also plans to continue expanding its VeriStrat and GeneStrat lung cancer tests. The former is a proteomic test for guiding therapy in non-small cell lung cancer, and the latter is a genetic test that analyzes circulating tumor DNA and RNA to help guide treatment decisions.

"By focusing on clinically actionable results for patients, we are developing and commercializing blood tests offering fast results that help physicians treat patients with the most effective therapies," Biodesix CEO David Brunel said in a statement. "With the introduction of immunotherapies, it is more important than ever to invest in developing appropriate diagnostic tests for emerging therapies. Securing this investment allows us to continue to work for the patients we serve."